Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Enochian Biosciences Inc is a biotechnology business based in the US. Enochian Biosciences shares (ENOB) are listed on the NASDAQ and all prices are listed in US Dollars. Enochian Biosciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $5.72 |
|---|---|
| 52-week range | $2.86 - $13.78 |
| 50-day moving average | $9.31 |
| 200-day moving average | $6.39 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.67 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.72 from 2022-01-14
| 1 week (2022-01-06) | -16.13% |
|---|---|
| 1 month (2021-12-17) | -27.69% |
| 3 months (2021-10-13) | -28.86% |
| 6 months (2021-07-16) | 25.16% |
| 1 year (2021-01-15) | 85.11% |
|---|---|
| 2 years (2020-01-17) | 10.21% |
| 3 years (2019-01-17) | 8.5 |
| 5 years (2017-01-17) | 444.76% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -9.76% |
| Return on equity TTM | -20.98% |
| Profit margin | 0% |
| Book value | $3.20 |
| Market capitalisation | $327.9 million |
TTM: trailing 12 months
We're not expecting Enochian Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Enochian Biosciences's shares have ranged in value from as little as $2.86 up to $13.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enochian Biosciences's is 0.4052. This would suggest that Enochian Biosciences's shares are less volatile than average (for this exchange).
Enochian Biosciences, Inc. , a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.